Literature DB >> 31123737

New ternary iron(iii) aminobisphenolate hydroxyquinoline complexes as potential therapeutic agents.

Cristina P Matos1, Yasemin Yildizhan2, Zelal Adiguzel2, Fernando R Pavan3, Débora L Campos3, João Costa Pessoa1, Liliana P Ferreira4, Ana Isabel Tomaz5, Isabel Correia1, Ceyda Acilan6.   

Abstract

In the quest for therapeutic iron-based metallodrugs, two new mixed-ligand iron(iii) complexes bearing the tripodal aminobisphenolate ligand N,N-bis(3,5-dimethyl-2-hydroxybenzyl)-N-(2-pyridylmethyl)amine (H2L) and hydroxyquinoline co-ligands, 8-hydroxyquinoline (8HQ) or 5-chloro-8-hydroxyquinoline (Cl8HQ), are synthesized, fully characterized and formulated as [Fe(L)(8HQ)] (1) and [Fe(L)(Cl8HQ)] (2), respectively. These high-spin Fe(iii) complexes are stable in aqueous solution in the presence of equimolar amounts of Bovine Serum Albumin (BSA), which indicates a likely binding interaction with the protein. In fact, binding constant log values at pH 7.4 for HSA of 5.08 and 6.35 were obtained for 1 and 2, respectively. Compounds 1 and 2 are cytotoxic against both human triple-negative breast adenocarcinoma (MDA-MB-231) and human cervical carcinoma (HeLa) cancer cells, and the activity is significantly improved by inclusion of the co-ligands 8HQ and Cl8HQ to the precursor complex Fe(L). Moreover, 1 and 2 are more active than 8HQ and Cl8HQ, particularly at lower incubation times tested, 24 and 48 h. Cells treated with the complexes display typical features of apoptosis as assessed by cellular morphology, DNA condensation and TUNEL analysis. COMET assays show that both drug candidates induce genomic damage in both cell lines. The complexes exhibit DNA cleavage activity and DNA damage that may be related to their ability to generate ROS. Overall, data supports that 1 and 2 are both active anticancer drug candidates within the low micromolar range. This is particularly interesting in the case of the breast MDA-MB-231 line, a model for triple-negative breast cancer that is an aggressive form of breast cancer, highly invasive and with limited treatment options and very poor prognosis. Furthermore, both complexes exhibited good anti-Mycobacterium tuberculosis activity, suggesting that 1 and 2 might have a wide spectrum of biological activity and justify further research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31123737     DOI: 10.1039/c9dt01193e

Source DB:  PubMed          Journal:  Dalton Trans        ISSN: 1477-9226            Impact factor:   4.390


  4 in total

1.  Copper(II) and oxidovanadium(IV) complexes of chromone Schiff bases as potential anticancer agents.

Authors:  Patrique Nunes; Yasemin Yildizhan; Zelal Adiguzel; Fernanda Marques; João Costa Pessoa; Ceyda Acilan; Isabel Correia
Journal:  J Biol Inorg Chem       Date:  2021-11-24       Impact factor: 3.358

2.  Liposomal Formulations of a New Zinc(II) Complex Exhibiting High Therapeutic Potential in a Murine Colon Cancer Model.

Authors:  Nádia Ribeiro; Melissa Albino; Andreia Ferreira; Cristina Escrevente; Duarte C Barral; João Costa Pessoa; Catarina Pinto Reis; Maria Manuela Gaspar; Isabel Correia
Journal:  Int J Mol Sci       Date:  2022-06-16       Impact factor: 6.208

3.  Bioinspired nonheme iron complex that triggers mitochondrial apoptotic signalling pathway specifically for colorectal cancer cells.

Authors:  Yool Lee; Chaeun Oh; Jin Kim; Myong-Suk Park; Woo Kyun Bae; Kyung Hyun Yoo; Seungwoo Hong
Journal:  Chem Sci       Date:  2021-12-11       Impact factor: 9.825

4.  Understanding the Potential In Vitro Modes of Action of Bis(β-diketonato) Oxovanadium(IV) Complexes.

Authors:  Baris Sergi; Ipek Bulut; Ying Xia; Zoë A E Waller; Yasemin Yildizhan; Ceyda Acilan; Rianne M Lord
Journal:  ChemMedChem       Date:  2021-05-26       Impact factor: 3.466

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.